ArticleJournal of molecular histology2026
Comprehensive insight into the anti-dyslipidemic and pancreatic lipase inhibition activities of Clematis flammula L. and Fraxinus angustifolia Vahl. extracts using two animal models.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Clematis flammula and Fraxinus angustifolia leaves are commonly used in Algeria to treat inflammatory diseases, with potential hypolipidemic effects that have not been investigated so far. The present study explored the in vitro, ex vivo, and in vivo hypolipidemic effects of ethanolic leaf extracts from both plants using two animal models (mice and rabbits) with distinct lipid metabolism. Dyslipidemia was induced by oral administration of Triton X-100, once daily for three consecutive days. Immediately after each Triton X-100 administration, animals received plant extracts (100 and 200 mg/kg bw) or atorvastatin (10 mg/kg bw). Anti-lipase and anti-HMG-CoA reductase activities were evaluated using in vitro and ex vivo assays. Triton X-100 induced marked alterations in serum lipid profiles, characterized by increased LDL-C, VLDL-C, and total cholesterol levels, which were improved by C. flammula and F. angustifolia extracts, particularly at 200 mg/kg bw. While F. angustifolia exhibited greater hypolipidemic efficacy, the lack of improvement in total cholesterol in mice treated with C. flammula, in contrast to rabbits, may suggest species-dependent differences in lipid metabolism, potentially involving CETP-mediated cholesterol transport, which requires further experimental confirmation. In vitro anti-lipase assays showed greater inhibitory potency for F. angustifolia (IC50 = 3.55 µg/mL) than C. flammula (IC50 = 12.10 µg/mL). Both extracts inhibited HMG-CoA reductase activity by over 60% in vitro and ex vivo, with IC50 values of 90.06 and 96.57 µg/mL for F. angustifolia and C. flammula, respectively. Histological examination further supported the hypolipidemic effects of both extracts. Overall, these findings highlight C. flammula and F. angustifolia as promising natural sources of bioactive compounds with potential applications in managing hypercholesterolemia and dyslipidemia.
Indexed as
Identifiers
42918911What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.